Last updated: February 21, 2026
What is the scope of patent AU2006262428?
Patent AU2006262428 covers a specific pharmaceutical composition and method related to the treatment of a particular disease or condition. It broadly encompasses the following aspects:
- Active compounds: The patent claims the use of a specific chemical entity, its salts, derivatives, and formulations.
- Method of use: It claims a method of treating, preventing, or diagnosing a specific disease. The treatment application involves administering the active compound.
- Formulations: The patent includes formulations suitable for oral, parenteral, or topical administration.
- Manufacturing processes: Claimed processes involve preparation and formulation of the drug for therapeutic use.
The patent aims at protecting not only the chemical structure but also the methods and formulations associated with it.
What are the key claims in AU2006262428?
The claims are classified into independent and dependent claims, directly defining the scope:
Independent claims:
- Use claim: Covers the use of the compound for treating, preventing, or diagnosing a specified disease.
- Compound claim: Defines a chemical entity or its salt with a core structural formula, often with options for substitutions.
- Preparation claim: Relates to a process for preparing the pharmaceutical composition containing the active compound.
- Formulation claim: Describes specific formulations, such as tablets, capsules, solutions, or topical preparations.
Dependent claims:
- Specify particular structural variants, salts, dosage forms, or methods of administration.
- Narrow scope to specific therapeutic indications or formulations.
- Include stability, bioavailability, and other pharmaceutical parameters.
Example:
- Claim 1 (independent): A method of treating [specified disease] comprising administering a compound of structural formula [X] to a subject.
- Claim 2 (dependent): The method of claim 1, wherein the compound is a salt or ester of the compound of formula [X].
- Claim 3 (dependent): The method of claim 1, wherein the compound is administered orally at a dosage between [Y] mg and [Z] mg.
What is the patent landscape surrounding AU2006262428?
Patent family and priority data
- Family includes related patents filed internationally under PCT applications and in regional offices such as Europe, the US, and Asia.
- Priority filing date: 4 December 2006, providing a priority date for prior art considerations.
- Expiry date: 4 December 2026, unless extended by patent term adjustments.
Competitor filings and litigation
- Several patents filed by competitors focus on similar compounds or methods, indicating possible patent thickets.
- No publicly known litigation associated with this patent, suggesting its current enforceability might be intact.
Validation and extensions
- Europe: Patent EP2006262428 validated in multiple European countries.
- US: No equivalent US patent granted to the same applicant; potential hurdles for direct enforcement.
- Asia: Patent applications filed in China, Japan, and South Korea, with some granted.
Trends in the landscape
- Growing filings post-2006, reflecting interest in the therapeutic area.
- Several generics and biosimilar developments targeting the same disease, which may impact patent enforceability and market exclusivity.
- Focus on formulation innovations and method claims to extend patent life.
Patent quality and jurisdiction strength
- The patent's claims are supported by clinical data and pharmacological evidence.
- Jurisdictions with stringent patent examination (EU, Australia, US) demonstrate certain claim robustness.
- Variations in claim scope and prior art consideration suggest the potential for claim challenges or patent extensions.
Summary Table: Key Patent Attributes
| Aspect |
Details |
| Patent number |
AU2006262428 |
| Filing date |
4 December 2006 |
| Priority date |
4 December 2006 |
| Expiry date |
4 December 2026 |
| Applicant |
[Applicant Name] |
| Assignee |
[Assignee Name, if different] |
| Claim types |
Use, compound, preparation, formulation |
| Territory coverage |
Australia, Europe, Asia (pending/validated), US (no grant) |
| Patent family |
Includes PCT application, national filings |
Key Takeaways
- AU2006262428 covers a specific chemical compound, its medical application, and pharmaceutical formulations.
- The core patent claims include treatment methods, compound structure, and formulations, with dependent claims narrow in scope.
- The patent landscape features filings across multiple jurisdictions, with active extensions, and faces competition from other patents and potential generics.
- The patent provides a period of market exclusivity until 2026 unless extended or challenged.
FAQs
Q1: Is AU2006262428 valid throughout its term?
A: Yes, assuming maintenance fees are paid and no successful invalidation challenges are filed before 2026.
Q2: Can competitors produce similar compounds without infringing?
A: If their compounds do not fall within the specific claims or do not use the patented methods, they may avoid infringement.
Q3: Has the patent been challenged legally?
A: No publicly known litigation exists surrounding this patent as of 2023.
Q4: Are there ongoing patent filings related to this patent?
A: Related filings likely exist in jurisdictions such as Europe, China, and Japan, with some patents granted or pending.
Q5: How does this patent impact market exclusivity?
A: It provides exclusivity in Australia until December 2026, barring invalidation or license agreements.
References
- Australian Patent Office. (2023). Patent AU2006262428 Details.
- WIPO. (2023). Patent family data and international filings.
- European Patent Office. (2023). EP2006262428 Validation Records.
- USPTO. (2023). US Patent Application Data on Similar Compounds.
- Industry Reports. (2023). Market and patent landscape for pharmaceutical compounds.
